A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.

HomeResource LibraryFour things to think about: PVG in...
  • Compassionate Use
  • Named Patient Use
  • Expanded Access Use
  • Managed Access

These are all different types of Early Access Programs (EAPs) that deliver investigational treatments to patients with life-threatening conditions, who have no alternative treatment options available.

Here are four things to think about when considering pharmacovigilance (PVG) for EAPs.

  1. Safety data collection requirements vary across the different types of EAPs and geographic regions. In Europe, this even varies across Member States
  2. Some regions require EAP ICSR submissions to follow clinical trial reporting rules whilst others consider EAP ICSRs to be reported per post market reporting rules
  3. In addition to inclusion of EAP safety information in DSURs/IND annual safety reports, some regions may require an annual report specifically on use within that EAP, for which a section on safety observations will be required
  4. Cross reporting may be required, for example, FDA consider IND safety reports to be important safety information, regardless of whether the report originated from any other IND in which the Sponsor is providing the investigational drug

Bionical Emas are uniquely positioned to support you with your EAP pharmacovigilance requirements; Our PVG function work closely with Regulatory Affairs and the Bionical EAP division to ensure we have a thorough understanding of the regulatory basis of the EAP so that we can use our expertise to deliver a tailored PVG service.

How can we support you?

Our dedicated teams of experts are on hand to help should you require any additional resource or further information about our services.